Home›Research›Compare›AOD-9604 vs Eloralintide
Peptide ComparisonAOD-9604 vs Eloralintide
AOD-9604
Advanced Obesity Drug 9604
Half-life: 30–60 minutes
197 providers listed
Eloralintide
LY3841136
Half-life: Not published
1 providers listed
AOD-9604 and Eloralintide target different goals — AOD-9604 for selective fat tissue lipolysis via GH C-terminal fragment mechanism, Eloralintide for appetite suppression. They're compared here for reference, not as direct substitutes.
AOD-9604
Half-life
30–60 minutes
Eloralintide
Half-life
Not published
AOD-9604 and Eloralintide target different goals — AOD-9604 for GH / IGF Axis, Eloralintide for Metabolic. They're compared here for reference; there isn't a single “better” choice between them.
AOD-9604
Eloralintide
AOD-9604
Eloralintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…
About AOD-9604
AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.
About Eloralintide
Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AOD-9604
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Eloralintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.
AOD-9604
Eloralintide
Not enough vendor pricing yet.
Where to source these peptides
AOD-9604
197 listed
Browse directory →
Providers offeringEloralintide
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AOD-9604 vs Eloralintide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/aod-9604/eloralintide